4G Clinical

4G Clinical is a leader in randomization and trial supply management for the global life sciences industry, offering the only fully cloud-based, 100% configurable and flexible solution using natural language processing and integrated supply forecasting. 4G Clinical is headquartered in the Boston biotech corridor of Wellesley, Mass., with offices in Europe and Asia. First Analysis invested in 4G Clinical in 2019 and successfully exited its investment in 2021 as part of a more than $230 million growth equity investment by Goldman Sachs Asset Management.